CEO Share Purchase

Poolbeg Pharma

06/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221006:nRSF9515Ba&default-theme=true

RNS Number : 9515B  Poolbeg Pharma PLC  06 October 2022

Poolbeg Pharma plc

CEO Share Purchase

6 October 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the
'Company'), a clinical stage infectious disease pharmaceutical company with a
unique capital light clinical model, has been notified that Chief Executive
Officer, Jeremy Skillington, has purchased 718,733 ordinary shares of 0.02
pence each in the Company ("Ordinary Shares") at a share price of 4.78 pence
per share.

 

Following the purchase, Jeremy Skillington's beneficial interest in the
Company is 718,733 Ordinary Shares, representing 0.14 per cent. of the total
issued share capital.

 

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

"Following the significant levels of activity and excellent progress that has
been made across our growing asset portfolio over recent months, I am pleased
to now finally have the opportunity to purchase shares in the Company. Poolbeg
is entering a very exciting phase in its development with a number of
near-term value inflection points and I am confident in our potential to
create future value for the Company and our shareholders through advancing and
partnering our pipeline of infectious disease treatments."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 (as implemented into English law) ("MAR").

 

- Ends -

Enquiries

 Poolbeg Pharma Plc                                  +44 (0) 20 7183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 finnCap Ltd (Nominated Adviser & Joint Broker)      +44 (0) 20 7220 0500

 Geoff Nash, James Thompson, Charlie Beeson,

Sunila de Silva (ECM), Nigel Birks

 Singer Capital Markets (Joint Broker)               +44 (0) 20 7496 3000

 Phil Davies, Sam Butcher
 J&E Davy (Joint Broker)                             +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Instinctif Partners                                 +44 (0) 20 7457 2020

 Melanie Toyne Sewell, Rozi Morris, Tim Field        poolbeg@instinctif.com

 

About Poolbeg Pharma

 

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company,
with a unique capital light clinical model which aims to develop multiple
products faster and more cost effectively than the conventional biotech model.
The Company, headquartered in London, is led by a team with a track record of
creation and delivery of shareholder value and aspires to become a "one-stop
shop" for pharma and biotech seeking mid-stage products to license or acquire.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025.

 

With its initial assets from Open Orphan plc (https://www.openorphan.com/) ,
an industry leading infectious disease and human challenge trials business,
Poolbeg has access to knowledge, experience, and clinical data from over 20
years of human challenge trials. The Company is using these insights to
acquire new assets as well as reposition clinical stage products, reducing
spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza (POLB 001) which has commenced
its LPS human challenge trial with initial results expected by year end 2022;
a first-in-class, intranasally administered RNA-based immunotherapy for
respiratory virus infections (POLB 002); and a vaccine candidate for
Melioidosis (POLB 003). The Company is also developing an oral vaccine
delivery platform and is progressing two artificial intelligence (AI)
programmes to accelerate the power of its human challenge model data and
biobank, with results from the first programme expected by year end 2022.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

Notification of transactions by Directors, Persons Discharging Managerial
Responsibilities ("PDMRs") and persons closely associated with them.

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Jeremy Skillington
 2.  Reason for the Notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Poolbeg Pharma plc
 b)  LEI                                                          213800UZ8WJLWYHBFL52
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary shares of 0.02 pence each
     Identification code                                          GB00BKPG7Z60
 b)  Nature of the Transaction                                    Purchase of ordinary shares
 c)  Price(s) and volume(s)                                       Price       Volume
                                                                  4.78 pence  718,733
 d)  Aggregated information                                       As above

     -     Aggregated volume

     -     Price
 e)  Date of the transaction                                      05/10/2022
 f)  Place of the transaction                                     London Stock Exchange

d)

Aggregated information

-     Aggregated volume

-     Price

As above

e)

Date of the transaction

05/10/2022

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDGBDGLBGDGDU